AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01425840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
Study NCT02063815 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fissure sealant application
Study NCT02107469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sida cordifolia roots
Description: Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner
Study NCT02107469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phyllanthus niruri
Description: Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.
Study NCT02107469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sida cordifolia roots extract
Description: gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal
Study NCT02107469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phyllanthus niruri extract
Description: gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal
Study NCT02107469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sida cordifolia placebo
Description: 300mg inert Maltodextrin in gelatine capsule. 2 capsules given 2 times a day orally with warm water before meals
Study NCT02107469 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phyllanthus niruri placebo
Description: 300mg inert Maltodextrin in gelatine capsule. 2 capsules given 3 times a day orally with warm water before meals
Study NCT03475433 — intervention group
Intervention type: DEVICE
Intervention: Actigraphy device
Description: Both groups will receive an actigraphy device that will passively measure their movement data.
Study NCT01757379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C-labeled Acetate
Description: 400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)
Study NCT01757379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C-labeled propionate
Description: 340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)
Study NCT01757379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C-labeled butyrate
Description: 990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)
Study NCT01757379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 15 g of inulin dissolved in 200 ml of water
Study NCT00835796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg tablets
Description: 1 x 5 mg, single dose fasting
Study NCT00835796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PROSCAR® 5mg tablets
Description: 1 x 5 mg, single dose fasting
Study NCT06516172 — intervention group
Intervention type: OTHER
Intervention: Comprehensive disease-specific rehabilitation
Description: Participation in (a) inpatient rehabilitation, (b) outpatient centre-based, (c) outpatient digitally-enhanced centre- and home-based, or (d) outpatient home-based digital/tele rehabilitation.~Duration is 3 weeks for inpatient and 12 weeks for outpatient programmes.
Study NCT01230229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting
Description: The stent should be deployed percutaneously, appropriate stent(s) size selected based upon the angiogram. The diameter must be 1-2 mm larger than the vessel. Length is chosen to cover lesion with one stent if possible. The choice of brand will be made through random selection among those offering possibility to cover the lesion with one stent. If more than one stent is required, overlap between 0.5 and 1 cm is acceptable. Postdilatation must be performed with a PTA balloon shorter than the length and less than the diameter of the stent. An angiogram should be made to compare the pre- and post-implant minimum lumen diameters. The non-diseased artery diameters shall be measured and residual % stenosis calculated.
Study NCT01230229 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best medical treatment
Description: Patients randomised to conservative treatment will receive appropriate medication with target levels of cholesterol 4,5 mmol/l, LDL 2,5 mmol/l and blood pressure level of 130/80 mmHg in addition to instruction how to engage in an exercise program. Each patient will receive a 'step-meter' which has to be carried during all activity during the first month and then during one week before each follow up visit. Step-meter read-outs will be recorded during each follow up visit. Smokers will be actively advised to quit smoking.
Study NCT02131077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-TI
Study NCT02131077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02260063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinastine syrup
Study NCT02260063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinastine tablets
Study NCT01116791 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)
Description: * CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)~* HIPC is administered immediately after CRS
Study NCT04599842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane block is performed by giving local anesthetic to the plan between the erector spinae muscle and the transverse process.
Study NCT03302949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lacprodan® DI-8090
Description: Whey protein concentrate. 100g powder contains 392 kcal (1646 kJ), hereof 80% protein.
Study NCT03413774 — intervention group
Intervention type: PROCEDURE
Intervention: vaginal swab
Description: high vaginal and Endocrvical swabs for bacterial, protozoal and chlamydial infection- examined by PCR
Study NCT03862573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
Study NCT03900039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Highly Cross Linked Polyethylene and oxidized zirconium femoral head
Description: Differing bearing surfaces:~1. Conventional polyethylene versus cobalt Chrome heads~2. Conventional polyethylene versus Oxidized Zirconium heads~3. Highly Cross-linked polyethylene versus Cobalt Chrome heads~4. Highly Cross-linked polyethylene versus Oxidized Zirconium heads
Study NCT03900039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Highly Cross Linked Polyethylene and oxidized zirconium femoral head
Description: Differing bearing surfaces:~1. Conventional polyethylene versus cobalt Chrome heads~2. Conventional polyethylene versus Oxidized Zirconium heads~3. Highly Cross-linked polyethylene versus Cobalt Chrome heads~4. Highly Cross-linked polyethylene versus Oxidized Zirconium heads
Study NCT02533466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium fluoride + potassium nitrate
Description: Marketed toothpaste containing 1450ppm fluoride as sodium fluoride and 5% potassium nitrate
Study NCT02533466 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Potassium nitrate
Description: Experimental toothpaste containing 5% potassium nitrate
Study NCT01820091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folotyn
Description: A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.
Study NCT01820091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fusilev
Description: Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.
Study NCT01063244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: foley balloon only
Description: place foley balloon only in cervix
Study NCT01063244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: foley balloon with weight attached
Description: foley balloon with 1000cc IV bag attached
Study NCT02392689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Description: Procalcitonin guided antibiotic therapy
Study NCT03638063 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine Triphosphate
Description: Adenosine Triphosphate aerosol
Study NCT03638063 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: capsaicin
Description: capsaicin aerosol
Study NCT02542462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix®,
Description: Single oral dose of licensed rotavirus vaccine given alone
Study NCT02542462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix®, with other routine vaccines
Description: Single oral dose of licensed rotavirus vaccine given with other routine vaccines
Study NCT02542462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq®,
Description: Single oral dose of licensed rotavirus vaccine given alone
Study NCT02542462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq®, with other routine vaccines
Description: Single oral dose of licensed rotavirus vaccine given with other routine vaccines
Study NCT00459407 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given orally
Study NCT00459407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00459407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT00459407 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT00459407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT00459407 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT00459407 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04281576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L(P)
Description: Patients receive continuous TTFields treatment using the NovoTTF-100L(P) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
Study NCT04281576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m\^2 intravenous infusion will be administered once every 3 weeks
Study NCT04281576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m\^2 taken by mouth, twice daily on day 1-14, 3 weeks per cycle
Study NCT04281576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (HER-2 positive patients only) intravenous infusion will be administered once every 3 weeks on Day 1 of each cycle. First dose is 8mg/kg, followed by 6 mg/kg.
Study NCT01712438 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human cl rhFVIII
Study NCT04514367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: Intravenous Infusion
Study NCT00726323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: foretinib (formerly GSK1363089 or XL880)
Description: treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
Study NCT01396785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 33525
Description: Daily for 14 days
Study NCT01396785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily for 14 days
Study NCT04476680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Pure Encapsulations' manufacturing facility is a US Food and Drug Administration (FDA) inspected and NSF International Good Manufacturing Practices registered company.
Study NCT03566550 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans
Description: Repeated MRI scans imaging digestion of standard meals
Study NCT04333433 — intervention group
Intervention type: DEVICE
Intervention: PRESERFLO® MicroShunt
Description: Device surgically implanted
Study NCT04333433 — intervention group
Intervention type: PROCEDURE
Intervention: Trabeculectomy
Description: The procedure involves removal of a small portion of the trabecular meshwork and adjacent scleral tissue. Aqueous humor then drains into the subconjunctival space, creating a bleb on the external part of the eye, where it diffuses away.
Study NCT03070457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early discharge
Description: Patients randomised to early discharge or not
Study NCT03070457 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional protocol
Description: Discharge as usually done 48-72 hours after surgery
Study NCT01926379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination intervention components
Description: The CIP will contain programmatic, structural, and psychosocial components, including:~1. use of a clinical algorithm by providers;~2. identification of HIV-infected family members eligible for IPT, using an ICAP-developed family care enrollment form (ICAP - International Center for AIDS Care and Treatment Programs);~3. review of monitoring data on IPT initiation and adherence during monthly multidisciplinary team meetings;~4. reimbursement of transportation costs for monthly clinic visits; and~5. real-time adherence support using IVR via mobile phones and trained Peer Educators.
Study NCT01926379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid Prevention Therapy
Description: Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to prevent progression to active TB disease.
Study NCT01926379 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Isoniazid Prevention Therapy
Description: Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to prevent progression to active TB disease.
Study NCT03207828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Description: The Brief Behavioral Activation Treatment for Depression (Lejuez, Hopko, Acierno, Daughters, \& Pagoto, 2011; Lejuez, Hopko, LePage, Hopko, and McNeil; 2001) will be used. It aims are (1) to increase engagement with activities associated with pleasure or mastery experiences; (2) decrease engagement with activities that maintain or increase the risk of depression; (3) and remove the barriers that limit the access to gratification. The sessions of therapy are well structured and described in its manual. The protocol was originally designed to be applied individually. However, for the present research, it will be adjusted to be applied in group sessions (5-8 participants). Materials will be also adjusted to be use with Chilean population. Treatment core aspects will not be altered. The treatment will last 10 sessions over two months. Two psychologist trained in behavioral activation will lead the sessions.
Study NCT03207828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.
Study NCT03207828 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.
Study NCT05372575 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13 PAC study
Description: To test the serotype-specific IgG geometric mean concentration (GMC) and MOPA geometric mean titers (GMT) for each of the pneumococcal serotypes measured at the time of diagnosis of clinical pneumonia.
Study NCT03553238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide will be administrated at a dose of 10mg/day in PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Adriamycin will be added to Consolidation-Module of PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: VP-16 will be added to Consolidation-Module of PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: AraC will be added to Consolidation-Module of PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Bone marrow aspiration and additional tests will be performed in all module of PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal injection
Description: Intrathecal injection chemotherapy will be performed in PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be performed for mediastinum and/or central nervous system leukemia in PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NGS
Description: Next-Generation-Sequencing (NGS) will be performed in PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Allo-HSCT will be performed for patients with available donor in PDT-ETP-ALL protocol.
Study NCT03553238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Flow-MRD
Description: Flow-MRD will be added to PDT-ETP-ALL for bone marrow and cerebrospinal fluid samples.
Study NCT03553238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FISH
Description: FISH will be performed in PDT-ETP-ALL for bone marrow samples.
Study NCT03553238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Flow immunophenotyping
Description: Flow immunophenotyping will be performed in PDT-ETP-ALL protocol.